THE UPLYFT COLLECTIVE
Weekly Intelligence Brief | Week of November 9, 2026
The Signal
For almost two decades, the wager behind CVS Health was that healthcare businesses become more valuable as they become more connected. The company bought Caremark in 2007 and Aetna in 2018, bringing an insurer, a company that manages prescription-drug benefits, clinics and one of America's largest pharmacy chains under the same roof. Last week, CVS Health took that wager in the opposite direction. It plans to split into two publicly traded companies, one centered on insurance, pharmacy benefits and care delivery, the other on roughly 9,000 pharmacies, mail pharmacy, MinuteClinic and Health100. The separation is expected in the first half of 2028. [cvshealth.com], [investors....health.com]
The instinct to redraw boundaries ran through the week. Aspen Pharmacare sold the European rights to a women's-health product but kept several ways to earn money from it. Blackstone Life Sciences committed $455 million to a medical-device program run by Boston Scientific. A day later, Nurix Therapeutics lost the prospect of future payments when Sanofi ended development of a partnered drug. In Washington, Medicare also began pulling apart two familiar payment arrangements, one for maternity care and another for drugs hospitals buy at a discount through the federal 340B program. [listcorp.com], [blackstone.com], [nasdaq.com], [ama-assn.org], [cms.gov]
These are very different decisions. What connects them is a distinction that becomes visible only when familiar structures come apart: ownership, economics and control do not necessarily travel together.
That is the question worth carrying into Monday. When a company, contract or payment arrangement is pulled apart, what moves, what keeps earning, and who still has the power to stop?
What Smart Money Is Watching: When CVS Health files the detailed documents for its separation, look beyond the org chart. The more revealing question will be which commercial relationships between CVS Caremark and CVS Pharmacy survive after they answer to different shareholders.
The Capital Tape
Three transactions make the week's central distinction visible from different angles: having money tied to an asset is not the same as controlling what happens to it.
1. CVS Health tests the limits of integration
The planned separation puts Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health into a healthcare-solutions company led by David Joyner. Prem Shah will lead CVS Pharmacy, built around approximately 9,000 pharmacies, mail pharmacy, MinuteClinic and Health100. CVS Health expects the tax-free separation to be completed in the first half of 2028. [cvshealth.com], [prnewswire.com]
The official rationale is focus. The more interesting consequence is that a tension currently managed inside one company becomes a negotiation between two. Caremark negotiates pharmacy economics on behalf of its clients, while CVS Pharmacy operates one of the country's largest pharmacy networks. After the split, those businesses will sit across a negotiating table rather than inside the same corporate structure.
That makes the agreements left behind almost as important as the assets being divided. If the two businesses continue relying heavily on one another after separation, the eventual contracts between them may tell investors as much about the economics of the old CVS Health as the breakup itself.
Prediction | Low-to-medium confidence: Expect another vertically integrated healthcare company to face stronger investor pressure over the next four to six quarters to explain why businesses that work together must also remain under the same corporate owner.
Decision question: If one part of your company is another part's customer, supplier and competitor, which relationship would still make sense if they stopped sharing a parent?
2. Aspen Pharmacare sells the asset and keeps part of the economics
Aspen Pharmacare agreed to sell the European commercial rights and intellectual property for Ovestin, an estriol treatment for menopausal symptoms, to Ennogen Healthcare International for €197 million, plus roughly €4 million for inventory. Ovestin generated about $45 million in revenue and $14 million in profit after tax in Aspen Pharmacare's 2026 financial year. [listcorp.com], [live.euronext.com]
The sale price tells only part of the story. Aspen Pharmacare will continue manufacturing and supplying the active ingredient and finished cream under agreements with an initial ten-year term. It will also receive €1 million a month for five years for support services, or €60 million in total, while a separate transitional arrangement allows it to earn additional distribution income. [listcorp.com], [africa.bus...nsider.com]
In practical terms, Ennogen Healthcare International bought the right to commercialize the product in Europe. Aspen Pharmacare gave up ownership while preserving several ways to earn money from the asset.
That model may be particularly relevant in women's health, where established products can struggle for attention inside larger companies focused on newer drugs. A specialist owner can invest more deliberately in the brand while the former owner remains its manufacturer or supplier.
Prediction | Low-to-medium confidence: Watch for more established women's-health products to move into specialist companies while former owners retain manufacturing, distribution or service agreements.
Decision question: If you sold a mature product tomorrow, which sources of revenue would actually require you to keep owning it?
3. When someone else controls the asset your return depends on
On November 2, Blackstone Life Sciences committed $455 million to help fund development of Boston Scientific's VITALYST system, a small heart pump intended for patients whose hearts can no longer pump enough blood after a heart attack. This is the first time the two companies have co-funded development of a Boston Scientific product. [blackstone.com]
A day later, Nurix Therapeutics provided the cautionary version of that arrangement. Sanofi discontinued the first human trial of SAR448272, an experimental drug for inflammatory disease, and ended the program. Nurix Therapeutics said it therefore no longer expected any future milestone payments or royalties associated with the drug. [nasdaq.com]
The decision was not described as a failed clinical trial or a safety problem in patients. Sanofi subsequently told analysts that emerging findings from research conducted before or alongside the human study did not support continuing development of this particular molecule in eczema. The scientific judgment may have been entirely reasonable. Commercially, however, the important fact is that Sanofi controlled whether the program continued while Nurix Therapeutics owned future payments that depended on that decision. [biopharmadive.com]
A royalty on an unfinished drug is therefore not just a claim on future sales. It is also a claim on another company's willingness to keep developing it.
Prediction | Medium confidence: If this becomes a broader pattern, investors funding drug and device programs they do not control should start asking for more protection, including earlier access to information and clearer compensation if a sponsor ends a program.
Decision question: For every royalty or milestone payment you expect to receive, who can make it disappear, and what protection do you have if they do?
The Regulatory Inflection
Maternity billing is being rebuilt after decades of bundling care together.
For years, US maternity care has largely been billed through global codes that package months of prenatal care, delivery and postpartum services together. The system is simple, but it no longer reflects how many pregnancies are actually managed. A patient may see several doctors or care teams across different locations, while the billing system can make all that work look like one service. [ama-assn.org]
Beginning January 1, that structure changes. The 2027 billing system deletes 17 maternity codes, adds 12 and revises six. Instead of treating most of the pregnancy as a single package, it separates care into four phases: prenatal care, management of labor, delivery and postpartum care. Prenatal and postpartum visits will generally be billed one encounter at a time. The American Medical Association says the goal is better transparency, clearer attribution of who provided care and better data about what happens across a pregnancy. [ama-assn.org], [ama-assn.org]
The result is more than an administrative exercise. Insurer contracts that reference the old codes need review. Billing software and electronic health records need updating. Pregnancies that begin this year and continue into 2027 need special handling because services performed in 2026 remain subject to the old rules. [ams-solutions.com], [vmghealth.com]
There is also a longer-term opportunity hidden inside the inconvenience. More detailed claims should make it easier to see who delivered each piece of care, where money is being spent and where patients may be falling through gaps between prenatal care, delivery and postpartum follow-up. That may ultimately be more important than the billing change itself.
Prediction | Medium confidence: Through 2027, the first significant spending around the maternity transition will go toward billing systems, contract updates and data rather than new clinical services.
Why this matters for us: Medicare represents only part of the US maternity market. The larger economic question is how state Medicaid programs and commercial insurers implement the new framework.
Decision question: Which of your contracts, software systems and payment schedules contains a maternity code that disappears January 1, and who is responsible for replacing it?
Source: American Medical Association, CPT 2027 maternity-care changes. [ama-assn.org], [ama-assn.org]
The Coverage Desk
Medicare just changed where billions of dollars from discounted drugs will land.
The federal 340B program allows eligible hospitals and clinics serving vulnerable populations to buy certain medicines at steep discounts. When those medicines are given to Medicare patients, hospitals receive a Medicare payment for the drug. The difference between the discounted purchase price and Medicare's reimbursement can be an important source of hospital revenue.
Beginning January 1, Medicare will sharply reduce that reimbursement. Hospitals currently receive the drug's average sales price plus 6%. Under the new rule, qualifying 340B drugs will generally be paid at average sales price minus 28%. CMS estimates the change will reduce Medicare drug spending by $4.35 billion in 2027 and lower patients' out-of-pocket costs by $1.1 billion. A Medicare patient receiving one of the affected drugs is expected to save about $900 on average. [cms.gov], [beckershos...review.com]
The $4.35 billion does not simply disappear from hospital reimbursement. The policy must be budget neutral, so CMS will shift an equivalent amount into higher payments for other hospital outpatient services. In plain English, hospitals that rely heavily on profits from discounted drugs are more exposed, while hospitals that deliver more non-drug outpatient care may get more of the offset. [beckershos...review.com], [beckershos...review.com]
A separate policy makes the calculation more complicated. CMS is also recovering $7.8 billion in earlier non-drug payments linked to a previous 340B policy that was later struck down. Beginning in 2027, affected hospitals will see that annual reduction increase from 0.5% to 2%, with the recovery expected to run through 2031. [hfma.org], [beckershos...review.com]
The important number, then, is not the national $4.35 billion. It is the number for each hospital. Two health systems in the same federal program can experience the changes very differently depending on which drugs they use, how much outpatient care they provide and whether they are affected by the separate repayment adjustment.
Prediction | Medium confidence: Expect reliance on 340B revenue to become a more important factor in hospital sales planning, customer segmentation and investment analysis.
Decision question: Can your commercial team explain how the new Medicare rules affect your three largest hospital customers without asking the customers for the answer?
Sources: CMS 2027 Hospital Outpatient Final Rule and related implementation analysis. [cms.gov], [hfma.org]
Career, Board & Capital
The professional advantage emerging from this week's news is not knowing every headline first. It is being able to follow the money after the headline.
That work increasingly crosses traditional job descriptions. Finance understands the numbers. Market-access teams understand how insurers and government programs pay. Commercial teams understand the customer. Corporate-development teams understand the deal. The strategically valuable leader can connect those perspectives and explain where revenue comes from, which agreement governs it, who controls the critical decision and what could interrupt the payment.
Marked up: leaders who can connect operating decisions to their financial consequences.
Marked down: analysis that stops at purchase price, company valuation or headline deal size.
Board question: Which important sources of revenue depend on decisions made outside the company?
The Syndicate Desk
This week's policy changes point to two practical investment screens.
Maternity billing and data infrastructure. Look beyond another documentation tool. The stronger company will already handle meaningful volumes of maternity claims, understand the new billing rules and be able to demonstrate fewer rejected claims, cleaner insurer contracts or better visibility into the cost and quality of care.
Hospital-level 340B intelligence. National averages tell a commercial team very little about an individual hospital. The valuable product is one that can identify which customers are financially exposed to the Medicare changes, explain why and estimate how large the effect could be.
Building or backing something credible in either area? Write to hello@theuplyftcollective.com. We will route it to members who can help.
The Uplyft Lens: Three Moves for This Month
1. Audit maternity codes across your revenue systems. Use the American Medical Association's complete list of deleted codes to review insurer contracts, electronic health records, billing systems and rate schedules. Pay special attention to pregnancies that cross from 2026 into 2027. [ama-assn.org], [vmghealth.com]
2. Map your largest hospital customers against the 340B changes. Determine how much they depend on Medicare reimbursement for discounted drugs and how much other outpatient care they deliver. Keep the new drug-payment cut separate from the older $7.8 billion recovery policy. [cms.gov], [hfma.org]
3. Inventory future payments that somebody else can stop. For every royalty, milestone or earnout, record what triggers payment, who controls that event and what happens if the underlying product or program ends.
What We Think Happens Next
1. Maternity coding creates an administrative market before it creates a clinical one
Confidence: Medium | Through 2027. Providers face a fixed January deadline for a substantial billing change. That makes contract updates, billing systems, staff training and claims management the immediate market. New clinical models may follow, but they will take longer to design and scale. [ama-assn.org], [vmghealth.com]
What changes our mind: Commercial insurers and state Medicaid programs adopt the new system with few payment disputes, little additional administrative cost and no meaningful increase in rejected claims.
2. Investors ask for stronger protection when somebody else controls development
Confidence: Medium | 12 to 18 months. Outside capital increasingly helps fund expensive drug and device development. The question is whether investors respond to that dependency by demanding better access to scientific information, advance notice when a program is at risk or compensation when a sponsor chooses to stop development.
What changes our mind: Similar development financings continue through 2027 without stronger reporting requirements, termination payments or other contractual protections.
3. 340B becomes part of hospital-customer planning
Confidence: Medium | 12 to 24 months. Medicare's new policy reduces payment for 340B drugs while redirecting the savings into other outpatient services, meaning its effect varies hospital by hospital. [cms.gov], [beckershos...review.com]
What changes our mind: Companies selling to hospitals reach the second half of 2027 without changing customer segmentation, contract assumptions or revenue forecasts based on each hospital's exposure.
Keeping score
Last week's prediction that large drug companies would increasingly use option agreements to gain access to early research received another supporting example. Boehringer Ingelheim and SBP Group announced a partnership covering several potential cancer treatments. SBP Group will carry out the early development before Boehringer Ingelheim decides whether to license individual programs. SBP Group receives $358 million in upfront and near-term payments and could receive up to $7 billion more in option, development, regulatory and commercial payments, plus royalties. [boehringer...elheim.com]
The broader logic is straightforward: the larger company pays for access now but delays the bigger commitment until more evidence exists.
The Closing
The week's stories are different, but the lesson is consistent. A corporate parent can own two businesses that would negotiate differently if separated. A drug company can sell a product and continue earning from it. An investor can have millions tied to a program somebody else runs. A hospital can gain on one part of a Medicare rule while losing on another.
The headline tells you what changed. The more useful question is where the money goes next, and who still controls the decision that determines whether it gets there.
If something here is useful for a conversation you are having this week, forward it. If you are closer to one of these stories than we are, we would like to hear from you.
The Uplyft Collective
The Uplyft Collective is a private leadership community for people shaping strategy across healthcare, pharmaceuticals, biotechnology, medical technology and life sciences. Take your seat at the table.
Apply to The Uplyft Collective
